Fig. 4From: Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United StatesPair-wise cost-effectiveness acceptability curve (nivolumab vs. everolimus). ICER, incremental cost-effectiveness ratioBack to article page